Cargando…
CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy
Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779674/ https://www.ncbi.nlm.nih.gov/pubmed/36555280 http://dx.doi.org/10.3390/ijms232415638 |
_version_ | 1784856667607793664 |
---|---|
author | Bogacka, Joanna Pawlik, Katarzyna Ciapała, Katarzyna Ciechanowska, Agata Mika, Joanna |
author_facet | Bogacka, Joanna Pawlik, Katarzyna Ciapała, Katarzyna Ciechanowska, Agata Mika, Joanna |
author_sort | Bogacka, Joanna |
collection | PubMed |
description | Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3C. Chemokines activate specific receptors localized on the surface of various immune and nervous cells. Approximately twenty chemokine receptors have been identified, and each of these receptors is a seven-transmembrane G-protein coupled receptor. Recent studies provide new evidence that CC chemokine receptor 4 (CCR4) is important in the pathogenesis of many diseases, such as diabetes, multiple sclerosis, asthma, dermatitis, and cancer. This review briefly characterizes CCR4 and its ligands (CCL17, CCL22, and CCL2), and their contributions to immunological and neoplastic diseases. The review notes a significant role of CCR4 in nociceptive transmission, especially in painful neuropathy, which accompanies many diseases. The pharmacological blockade of CCR4 seems beneficial because of its pain-relieving effects and its influence on opioid efficacy. The possibilities of using the CCL2/CCL17/CCL22/CCR4 axis as a target in new therapies for many diseases are also discussed. |
format | Online Article Text |
id | pubmed-9779674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97796742022-12-23 CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy Bogacka, Joanna Pawlik, Katarzyna Ciapała, Katarzyna Ciechanowska, Agata Mika, Joanna Int J Mol Sci Review Chemokines and their receptors participate in many biological processes, including the modulation of neuroimmune interactions. Approximately fifty chemokines are distinguished in humans, which are classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C, and CX3C. Chemokines activate specific receptors localized on the surface of various immune and nervous cells. Approximately twenty chemokine receptors have been identified, and each of these receptors is a seven-transmembrane G-protein coupled receptor. Recent studies provide new evidence that CC chemokine receptor 4 (CCR4) is important in the pathogenesis of many diseases, such as diabetes, multiple sclerosis, asthma, dermatitis, and cancer. This review briefly characterizes CCR4 and its ligands (CCL17, CCL22, and CCL2), and their contributions to immunological and neoplastic diseases. The review notes a significant role of CCR4 in nociceptive transmission, especially in painful neuropathy, which accompanies many diseases. The pharmacological blockade of CCR4 seems beneficial because of its pain-relieving effects and its influence on opioid efficacy. The possibilities of using the CCL2/CCL17/CCL22/CCR4 axis as a target in new therapies for many diseases are also discussed. MDPI 2022-12-09 /pmc/articles/PMC9779674/ /pubmed/36555280 http://dx.doi.org/10.3390/ijms232415638 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bogacka, Joanna Pawlik, Katarzyna Ciapała, Katarzyna Ciechanowska, Agata Mika, Joanna CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title | CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title_full | CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title_fullStr | CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title_full_unstemmed | CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title_short | CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy |
title_sort | cc chemokine receptor 4 (ccr4) as a possible new target for therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779674/ https://www.ncbi.nlm.nih.gov/pubmed/36555280 http://dx.doi.org/10.3390/ijms232415638 |
work_keys_str_mv | AT bogackajoanna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy AT pawlikkatarzyna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy AT ciapałakatarzyna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy AT ciechanowskaagata ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy AT mikajoanna ccchemokinereceptor4ccr4asapossiblenewtargetfortherapy |